Abstract:Reductive stress is characterized by an excess of cellular electron donors and can be linked with various human pathologies including cancer. We developed melanoma cell lines resistant to reductive stress agents: rotenone (ROTR), n-acetyl-L-cysteine, (NACR), or dithiothreitol (DTTR). Resistant cells divided more rapidly and had intracellular homeostatic redox-couple ratios that were shifted towards the reduced state. Resistance caused alterations in general cell morphology, but only ROTR cells had significant changes in mitochondrial morphology with higher numbers that were more isolated, fragmented and swollen, with greater membrane depolarization and decreased numbers of networks. These changes were accompanied by lower basal oxygen consumption and maximal respiration rates. Whole cell flux analyses and mitochondrial function assays showed that NACR and DTTR preferentially utilized tricarboxylic acid (TCA) cycle intermediates, while ROTR used ketone body substrates such as D, L-β-hydroxybutyric acid. NACR and DTTR cells had constitutively decreased levels of reactive oxygen species (ROS), although this was accompanied by activation of nuclear factor erythroid 2-related factor 2 (Nrf2), with concomitant increased expression of the downstream gene products such as glutathione S-transferase P (GSTP). Further adaptations included enhanced expression of endoplasmic reticulum proteins controlling the unfolded protein response (UPR). Although expression patterns of these UPR proteins were distinct between the resistant cells, a trend implied that resistance to reductive stress is accompanied by a constitutively increased UPR phenotype in each line. Overall, tumor cells, although tolerant of oxidative stress, can adapt their energy and survival mechanisms in lethal reductive stress conditions.

Reductive carboxylation supports redox homeostasis during anchorage-independent growth

Reductive Stress in Cancer: Coming out of the Shadows

"Reductive stress" the overlooked side of cellular redox modulation in cancer: opportunity for design of next generation redox chemotherapeutics

Adaptive changes in tumor cells in response to reductive stress

Redox remodeling of central metabolism as a driving force for cellular protection, proliferation, differentiation, and dysfunction

Supplemental Figure 8 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells

Role of Reductive versus Oxidative Stress in Tumor Progression and Anticancer Drug Resistance

The redox requirement and regulation during cell proliferation

Cellular metabolic and autophagic pathways: traffic control by redox signaling

Tracing the Electron Flow in Redox Metabolism: the Appropriate Distribution of Electrons is Essential to Maintain Redox Balance in Cancer Cells.

Oxidation of Alpha-Ketoglutarate is Required for Reductive Carboxylation in Cancer Cells with Mitochondrial Defects.

Targeting the Redox Landscape in Cancer Therapy

Redox Signaling: Potential Arbitrator of Autophagy and Apoptosis in Therapeutic Response

The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context

Redox metabolism maintains the leukemogenic capacity and drug resistance of AML cells

Redox regulation and its emerging roles in cancer treatment

Malate dehydrogenase (MDH) in cancer: a promiscuous enzyme, a redox regulator, and a metabolic co-conspirator

Regulation of cancer cell lipid metabolism and oxidative phosphorylation by microenvironmental acidosis

MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions

Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?

Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis